EMA Refused: Dropcys (mercaptamine) — Lucane Pharma

View source ↗

Summary

The EMA refused marketing authorization for Dropcys (mercaptamine) by Lucane Pharma, for corneal diseases and cystinosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Diseases
• Cystinosis

Drugs mentioned

• Dropcys (mercaptamine)

Snippet

Status: Refused. Therapeutic area: Corneal Diseases;Cystinosis. MAH: Lucane Pharma. Decision date: 24/06/2016. Orphan medicine